The six and 12-month results from the STAR-II trial on MINIjectTM have been reported in the latest issue of Ophthalmology Times.
According to the article, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device, MINIject, may offer a valuable bleb-free treatment option for patients with glaucoma who require low target pressures. MINIject lowered mean IOP in the STAR-II trial from 24.6mmHg at baseline to 15.1mmHg at one year, a reduction of 38%, while more than halving the mean number of medications required.
Moreover, the article highlighted that no endothelial cell loss or migration was detected in the trial.
“Overall, MINIject was found to be very safe, and forty-five percent of patients were medication free at the 1-year time point,”
stated Julián García-Feijoó, MD, PhD, one of the STAR-II trial investigators, professor of ophthalmology and chairman of the Department of Ophthalmology at San Carlos Clinical Hospital, Complutense University of Madrid, Spain, commenting on the STAR-II trial results in the article.
To view the full article: click here.